Cost-effectiveness analysis of lifestyle intervention in obese infertile women

A. M. Van Oers, M. A.Q. Mutsaerts, J. M. Burggraaff, W. K.H. Kuchenbecker, D. A.M. Perquin, C. A.M. Koks, R. Van Golde, E. M. Kaaijk, J. M. Schierbeek, N. F. Klijn, Y. M. Van Kasteren, J. A. Land, B. W.J. Mol, A. Hoek, H. Groen, G. J.E. Oosterhuis, F. J. Broekmans, N. E.A. Vogel, C. B. Lambalk, M. F.G. Verberg & 7 others P. E.A.M. Mercelina, F. Van Der Veen, A. W. Nap, E. T.C.M. Gondrie, R. J.A.B. Mulder, J. P. De Bruin, behalf of the LIFEstyle study group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

STUDY QUESTION What is the cost-effectiveness of lifestyle intervention preceding infertility treatment in obese infertile women? SUMMARY ANSWER Lifestyle intervention preceding infertility treatment as compared to prompt infertility treatment in obese infertile women is not a cost-effective strategy in terms of healthy live birth rate within 24 months after randomization, but is more likely to be cost-effective using a longer follow-up period and live birth rate as endpoint. WHAT IS KNOWN ALREADY In infertile couples, obesity decreases conception chances. We previously showed that lifestyle intervention prior to infertility treatment in obese infertile women did not increase the healthy singleton vaginal live birth rate at term, but increased natural conceptions, especially in anovulatory women. Cost-effectiveness analyses could provide relevant additional information to guide decisions regarding offering a lifestyle intervention to obese infertile women. STUDY DESIGN, SIZE, DURATION The cost-effectiveness of lifestyle intervention preceding infertility treatment compared to prompt infertility treatment was evaluated based on data of a previous RCT, the LIFEstyle study. The primary outcome for effectiveness was the vaginal birth of a healthy singleton at term within 24 months after randomization (the healthy live birth rate). The economic evaluation was performed from a hospital perspective and included direct medical costs of the lifestyle intervention, infertility treatments, medication and pregnancy in the intervention and control group. In addition, we performed exploratory cost-effectiveness analyses of scenarios with additional effectiveness outcomes (overall live birth within 24 months and overall live birth conceived within 24 months) and of subgroups, i.e. of ovulatory and anovulatory women, women <36 years and ≥36 years of age and of completers of the lifestyle intervention. Bootstrap analyses were performed to assess the uncertainty surrounding cost-effectiveness. PARTICIPANTS/MATERIALS, SETTINGS, METHODS Infertile women with a BMI of ≥29 kg/m 2 (no upper limit) were allocated to a 6-month lifestyle intervention programme preceding infertility treatment (intervention group, n = 290) or to prompt infertility treatment (control group, n = 287). After excluding women who withdrew informed consent or who were lost to follow-up we included 280 women in the intervention group and 284 women in the control group in the analysis. MAIN RESULTS AND THE ROLE OF CHANCE Total mean costs per woman in the intervention group within 24 months after randomization were €4324 (SD €4276) versus €5603 (SD €4632) in the control group (cost difference of '€1278, P < 0.05). Healthy live birth rates were 27 and 35% in the intervention group and the control group, respectively (effect difference of '8.1%, P < 0.05), resulting in an incremental cost-effectiveness ratio of €15 845 per additional percentage increase of the healthy live birth rate. Mean costs per healthy live birth event were €15 932 in the intervention group and €15 912 in the control group. Exploratory scenario analyses showed that after changing the effectiveness outcome to all live births conceived within 24 months, irrespective of delivery within or after 24 months, cost-effectiveness of the lifestyle intervention improved. Using this effectiveness outcome, the probability that lifestyle intervention preceding infertility treatment was cost-effective in anovulatory women was 40%, in completers of the lifestyle intervention 39%, and in women ≥36 years 29%. LIMITATIONS, REASONS FOR CAUTION In contrast to the study protocol, we were not able to perform the analysis from a societal perspective. Besides the primary outcome of the LIFEstyle study, we performed exploratory analyses using outcomes observed at longer follow-up times and we evaluated subgroups of women; the trial was not powered on these additional outcomes or subgroup analyses. WIDER IMPLICATIONS OF THE FINDINGS Cost-effectiveness of a lifestyle intervention is more likely for longer follow-up times, and with live births conceived within 24 months as the effectiveness outcome. This effect was most profound in anovulatory women, in completers of the lifestyle intervention and in women ≥36 years old. This result indicates that the follow-up period of lifestyle interventions in obese infertile women is important. The scenario analyses performed in this study suggest that offering and reimbursing lifestyle intervention programmes in certain patient categories may be cost-effective and it provides directions for future research in this field. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The department of obstetrics and gynaecology of the UMCG received an unrestricted educational grant from Ferring pharmaceuticals BV, The Netherlands. B.W.J.M. is a consultant for ObsEva, Geneva. TRIAL REGISTRATION NUMBER The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1530.

LanguageEnglish
Pages1418-1426
Number of pages9
JournalHuman Reproduction
Volume32
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017

Keywords

  • anovulation
  • cost-effectiveness
  • infertility
  • lifestyle intervention
  • obesity
  • scenario analysis

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Van Oers, A. M., Mutsaerts, M. A. Q., Burggraaff, J. M., Kuchenbecker, W. K. H., Perquin, D. A. M., Koks, C. A. M., ... behalf of the LIFEstyle study group (2017). Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Human Reproduction, 32(7), 1418-1426. https://doi.org/10.1093/humrep/dex092
Van Oers, A. M. ; Mutsaerts, M. A.Q. ; Burggraaff, J. M. ; Kuchenbecker, W. K.H. ; Perquin, D. A.M. ; Koks, C. A.M. ; Van Golde, R. ; Kaaijk, E. M. ; Schierbeek, J. M. ; Klijn, N. F. ; Van Kasteren, Y. M. ; Land, J. A. ; Mol, B. W.J. ; Hoek, A. ; Groen, H. ; Oosterhuis, G. J.E. ; Broekmans, F. J. ; Vogel, N. E.A. ; Lambalk, C. B. ; Verberg, M. F.G. ; Mercelina, P. E.A.M. ; Van Der Veen, F. ; Nap, A. W. ; Gondrie, E. T.C.M. ; Mulder, R. J.A.B. ; De Bruin, J. P. ; behalf of the LIFEstyle study group. / Cost-effectiveness analysis of lifestyle intervention in obese infertile women. In: Human Reproduction. 2017 ; Vol. 32, No. 7. pp. 1418-1426.
@article{e7d7f647e5c54cac9935a136fc753c12,
title = "Cost-effectiveness analysis of lifestyle intervention in obese infertile women",
abstract = "STUDY QUESTION What is the cost-effectiveness of lifestyle intervention preceding infertility treatment in obese infertile women? SUMMARY ANSWER Lifestyle intervention preceding infertility treatment as compared to prompt infertility treatment in obese infertile women is not a cost-effective strategy in terms of healthy live birth rate within 24 months after randomization, but is more likely to be cost-effective using a longer follow-up period and live birth rate as endpoint. WHAT IS KNOWN ALREADY In infertile couples, obesity decreases conception chances. We previously showed that lifestyle intervention prior to infertility treatment in obese infertile women did not increase the healthy singleton vaginal live birth rate at term, but increased natural conceptions, especially in anovulatory women. Cost-effectiveness analyses could provide relevant additional information to guide decisions regarding offering a lifestyle intervention to obese infertile women. STUDY DESIGN, SIZE, DURATION The cost-effectiveness of lifestyle intervention preceding infertility treatment compared to prompt infertility treatment was evaluated based on data of a previous RCT, the LIFEstyle study. The primary outcome for effectiveness was the vaginal birth of a healthy singleton at term within 24 months after randomization (the healthy live birth rate). The economic evaluation was performed from a hospital perspective and included direct medical costs of the lifestyle intervention, infertility treatments, medication and pregnancy in the intervention and control group. In addition, we performed exploratory cost-effectiveness analyses of scenarios with additional effectiveness outcomes (overall live birth within 24 months and overall live birth conceived within 24 months) and of subgroups, i.e. of ovulatory and anovulatory women, women <36 years and ≥36 years of age and of completers of the lifestyle intervention. Bootstrap analyses were performed to assess the uncertainty surrounding cost-effectiveness. PARTICIPANTS/MATERIALS, SETTINGS, METHODS Infertile women with a BMI of ≥29 kg/m 2 (no upper limit) were allocated to a 6-month lifestyle intervention programme preceding infertility treatment (intervention group, n = 290) or to prompt infertility treatment (control group, n = 287). After excluding women who withdrew informed consent or who were lost to follow-up we included 280 women in the intervention group and 284 women in the control group in the analysis. MAIN RESULTS AND THE ROLE OF CHANCE Total mean costs per woman in the intervention group within 24 months after randomization were €4324 (SD €4276) versus €5603 (SD €4632) in the control group (cost difference of '€1278, P < 0.05). Healthy live birth rates were 27 and 35{\%} in the intervention group and the control group, respectively (effect difference of '8.1{\%}, P < 0.05), resulting in an incremental cost-effectiveness ratio of €15 845 per additional percentage increase of the healthy live birth rate. Mean costs per healthy live birth event were €15 932 in the intervention group and €15 912 in the control group. Exploratory scenario analyses showed that after changing the effectiveness outcome to all live births conceived within 24 months, irrespective of delivery within or after 24 months, cost-effectiveness of the lifestyle intervention improved. Using this effectiveness outcome, the probability that lifestyle intervention preceding infertility treatment was cost-effective in anovulatory women was 40{\%}, in completers of the lifestyle intervention 39{\%}, and in women ≥36 years 29{\%}. LIMITATIONS, REASONS FOR CAUTION In contrast to the study protocol, we were not able to perform the analysis from a societal perspective. Besides the primary outcome of the LIFEstyle study, we performed exploratory analyses using outcomes observed at longer follow-up times and we evaluated subgroups of women; the trial was not powered on these additional outcomes or subgroup analyses. WIDER IMPLICATIONS OF THE FINDINGS Cost-effectiveness of a lifestyle intervention is more likely for longer follow-up times, and with live births conceived within 24 months as the effectiveness outcome. This effect was most profound in anovulatory women, in completers of the lifestyle intervention and in women ≥36 years old. This result indicates that the follow-up period of lifestyle interventions in obese infertile women is important. The scenario analyses performed in this study suggest that offering and reimbursing lifestyle intervention programmes in certain patient categories may be cost-effective and it provides directions for future research in this field. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The department of obstetrics and gynaecology of the UMCG received an unrestricted educational grant from Ferring pharmaceuticals BV, The Netherlands. B.W.J.M. is a consultant for ObsEva, Geneva. TRIAL REGISTRATION NUMBER The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1530.",
keywords = "anovulation, cost-effectiveness, infertility, lifestyle intervention, obesity, scenario analysis",
author = "{Van Oers}, {A. M.} and Mutsaerts, {M. A.Q.} and Burggraaff, {J. M.} and Kuchenbecker, {W. K.H.} and Perquin, {D. A.M.} and Koks, {C. A.M.} and {Van Golde}, R. and Kaaijk, {E. M.} and Schierbeek, {J. M.} and Klijn, {N. F.} and {Van Kasteren}, {Y. M.} and Land, {J. A.} and Mol, {B. W.J.} and A. Hoek and H. Groen and Oosterhuis, {G. J.E.} and Broekmans, {F. J.} and Vogel, {N. E.A.} and Lambalk, {C. B.} and Verberg, {M. F.G.} and Mercelina, {P. E.A.M.} and {Van Der Veen}, F. and Nap, {A. W.} and Gondrie, {E. T.C.M.} and Mulder, {R. J.A.B.} and {De Bruin}, {J. P.} and {behalf of the LIFEstyle study group}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/humrep/dex092",
language = "English",
volume = "32",
pages = "1418--1426",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "7",

}

Van Oers, AM, Mutsaerts, MAQ, Burggraaff, JM, Kuchenbecker, WKH, Perquin, DAM, Koks, CAM, Van Golde, R, Kaaijk, EM, Schierbeek, JM, Klijn, NF, Van Kasteren, YM, Land, JA, Mol, BWJ, Hoek, A, Groen, H, Oosterhuis, GJE, Broekmans, FJ, Vogel, NEA, Lambalk, CB, Verberg, MFG, Mercelina, PEAM, Van Der Veen, F, Nap, AW, Gondrie, ETCM, Mulder, RJAB, De Bruin, JP & behalf of the LIFEstyle study group 2017, 'Cost-effectiveness analysis of lifestyle intervention in obese infertile women', Human Reproduction, vol. 32, no. 7, pp. 1418-1426. https://doi.org/10.1093/humrep/dex092

Cost-effectiveness analysis of lifestyle intervention in obese infertile women. / Van Oers, A. M.; Mutsaerts, M. A.Q.; Burggraaff, J. M.; Kuchenbecker, W. K.H.; Perquin, D. A.M.; Koks, C. A.M.; Van Golde, R.; Kaaijk, E. M.; Schierbeek, J. M.; Klijn, N. F.; Van Kasteren, Y. M.; Land, J. A.; Mol, B. W.J.; Hoek, A.; Groen, H.; Oosterhuis, G. J.E.; Broekmans, F. J.; Vogel, N. E.A.; Lambalk, C. B.; Verberg, M. F.G.; Mercelina, P. E.A.M.; Van Der Veen, F.; Nap, A. W.; Gondrie, E. T.C.M.; Mulder, R. J.A.B.; De Bruin, J. P.; behalf of the LIFEstyle study group.

In: Human Reproduction, Vol. 32, No. 7, 01.07.2017, p. 1418-1426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness analysis of lifestyle intervention in obese infertile women

AU - Van Oers, A. M.

AU - Mutsaerts, M. A.Q.

AU - Burggraaff, J. M.

AU - Kuchenbecker, W. K.H.

AU - Perquin, D. A.M.

AU - Koks, C. A.M.

AU - Van Golde, R.

AU - Kaaijk, E. M.

AU - Schierbeek, J. M.

AU - Klijn, N. F.

AU - Van Kasteren, Y. M.

AU - Land, J. A.

AU - Mol, B. W.J.

AU - Hoek, A.

AU - Groen, H.

AU - Oosterhuis, G. J.E.

AU - Broekmans, F. J.

AU - Vogel, N. E.A.

AU - Lambalk, C. B.

AU - Verberg, M. F.G.

AU - Mercelina, P. E.A.M.

AU - Van Der Veen, F.

AU - Nap, A. W.

AU - Gondrie, E. T.C.M.

AU - Mulder, R. J.A.B.

AU - De Bruin, J. P.

AU - behalf of the LIFEstyle study group

PY - 2017/7/1

Y1 - 2017/7/1

N2 - STUDY QUESTION What is the cost-effectiveness of lifestyle intervention preceding infertility treatment in obese infertile women? SUMMARY ANSWER Lifestyle intervention preceding infertility treatment as compared to prompt infertility treatment in obese infertile women is not a cost-effective strategy in terms of healthy live birth rate within 24 months after randomization, but is more likely to be cost-effective using a longer follow-up period and live birth rate as endpoint. WHAT IS KNOWN ALREADY In infertile couples, obesity decreases conception chances. We previously showed that lifestyle intervention prior to infertility treatment in obese infertile women did not increase the healthy singleton vaginal live birth rate at term, but increased natural conceptions, especially in anovulatory women. Cost-effectiveness analyses could provide relevant additional information to guide decisions regarding offering a lifestyle intervention to obese infertile women. STUDY DESIGN, SIZE, DURATION The cost-effectiveness of lifestyle intervention preceding infertility treatment compared to prompt infertility treatment was evaluated based on data of a previous RCT, the LIFEstyle study. The primary outcome for effectiveness was the vaginal birth of a healthy singleton at term within 24 months after randomization (the healthy live birth rate). The economic evaluation was performed from a hospital perspective and included direct medical costs of the lifestyle intervention, infertility treatments, medication and pregnancy in the intervention and control group. In addition, we performed exploratory cost-effectiveness analyses of scenarios with additional effectiveness outcomes (overall live birth within 24 months and overall live birth conceived within 24 months) and of subgroups, i.e. of ovulatory and anovulatory women, women <36 years and ≥36 years of age and of completers of the lifestyle intervention. Bootstrap analyses were performed to assess the uncertainty surrounding cost-effectiveness. PARTICIPANTS/MATERIALS, SETTINGS, METHODS Infertile women with a BMI of ≥29 kg/m 2 (no upper limit) were allocated to a 6-month lifestyle intervention programme preceding infertility treatment (intervention group, n = 290) or to prompt infertility treatment (control group, n = 287). After excluding women who withdrew informed consent or who were lost to follow-up we included 280 women in the intervention group and 284 women in the control group in the analysis. MAIN RESULTS AND THE ROLE OF CHANCE Total mean costs per woman in the intervention group within 24 months after randomization were €4324 (SD €4276) versus €5603 (SD €4632) in the control group (cost difference of '€1278, P < 0.05). Healthy live birth rates were 27 and 35% in the intervention group and the control group, respectively (effect difference of '8.1%, P < 0.05), resulting in an incremental cost-effectiveness ratio of €15 845 per additional percentage increase of the healthy live birth rate. Mean costs per healthy live birth event were €15 932 in the intervention group and €15 912 in the control group. Exploratory scenario analyses showed that after changing the effectiveness outcome to all live births conceived within 24 months, irrespective of delivery within or after 24 months, cost-effectiveness of the lifestyle intervention improved. Using this effectiveness outcome, the probability that lifestyle intervention preceding infertility treatment was cost-effective in anovulatory women was 40%, in completers of the lifestyle intervention 39%, and in women ≥36 years 29%. LIMITATIONS, REASONS FOR CAUTION In contrast to the study protocol, we were not able to perform the analysis from a societal perspective. Besides the primary outcome of the LIFEstyle study, we performed exploratory analyses using outcomes observed at longer follow-up times and we evaluated subgroups of women; the trial was not powered on these additional outcomes or subgroup analyses. WIDER IMPLICATIONS OF THE FINDINGS Cost-effectiveness of a lifestyle intervention is more likely for longer follow-up times, and with live births conceived within 24 months as the effectiveness outcome. This effect was most profound in anovulatory women, in completers of the lifestyle intervention and in women ≥36 years old. This result indicates that the follow-up period of lifestyle interventions in obese infertile women is important. The scenario analyses performed in this study suggest that offering and reimbursing lifestyle intervention programmes in certain patient categories may be cost-effective and it provides directions for future research in this field. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The department of obstetrics and gynaecology of the UMCG received an unrestricted educational grant from Ferring pharmaceuticals BV, The Netherlands. B.W.J.M. is a consultant for ObsEva, Geneva. TRIAL REGISTRATION NUMBER The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1530.

AB - STUDY QUESTION What is the cost-effectiveness of lifestyle intervention preceding infertility treatment in obese infertile women? SUMMARY ANSWER Lifestyle intervention preceding infertility treatment as compared to prompt infertility treatment in obese infertile women is not a cost-effective strategy in terms of healthy live birth rate within 24 months after randomization, but is more likely to be cost-effective using a longer follow-up period and live birth rate as endpoint. WHAT IS KNOWN ALREADY In infertile couples, obesity decreases conception chances. We previously showed that lifestyle intervention prior to infertility treatment in obese infertile women did not increase the healthy singleton vaginal live birth rate at term, but increased natural conceptions, especially in anovulatory women. Cost-effectiveness analyses could provide relevant additional information to guide decisions regarding offering a lifestyle intervention to obese infertile women. STUDY DESIGN, SIZE, DURATION The cost-effectiveness of lifestyle intervention preceding infertility treatment compared to prompt infertility treatment was evaluated based on data of a previous RCT, the LIFEstyle study. The primary outcome for effectiveness was the vaginal birth of a healthy singleton at term within 24 months after randomization (the healthy live birth rate). The economic evaluation was performed from a hospital perspective and included direct medical costs of the lifestyle intervention, infertility treatments, medication and pregnancy in the intervention and control group. In addition, we performed exploratory cost-effectiveness analyses of scenarios with additional effectiveness outcomes (overall live birth within 24 months and overall live birth conceived within 24 months) and of subgroups, i.e. of ovulatory and anovulatory women, women <36 years and ≥36 years of age and of completers of the lifestyle intervention. Bootstrap analyses were performed to assess the uncertainty surrounding cost-effectiveness. PARTICIPANTS/MATERIALS, SETTINGS, METHODS Infertile women with a BMI of ≥29 kg/m 2 (no upper limit) were allocated to a 6-month lifestyle intervention programme preceding infertility treatment (intervention group, n = 290) or to prompt infertility treatment (control group, n = 287). After excluding women who withdrew informed consent or who were lost to follow-up we included 280 women in the intervention group and 284 women in the control group in the analysis. MAIN RESULTS AND THE ROLE OF CHANCE Total mean costs per woman in the intervention group within 24 months after randomization were €4324 (SD €4276) versus €5603 (SD €4632) in the control group (cost difference of '€1278, P < 0.05). Healthy live birth rates were 27 and 35% in the intervention group and the control group, respectively (effect difference of '8.1%, P < 0.05), resulting in an incremental cost-effectiveness ratio of €15 845 per additional percentage increase of the healthy live birth rate. Mean costs per healthy live birth event were €15 932 in the intervention group and €15 912 in the control group. Exploratory scenario analyses showed that after changing the effectiveness outcome to all live births conceived within 24 months, irrespective of delivery within or after 24 months, cost-effectiveness of the lifestyle intervention improved. Using this effectiveness outcome, the probability that lifestyle intervention preceding infertility treatment was cost-effective in anovulatory women was 40%, in completers of the lifestyle intervention 39%, and in women ≥36 years 29%. LIMITATIONS, REASONS FOR CAUTION In contrast to the study protocol, we were not able to perform the analysis from a societal perspective. Besides the primary outcome of the LIFEstyle study, we performed exploratory analyses using outcomes observed at longer follow-up times and we evaluated subgroups of women; the trial was not powered on these additional outcomes or subgroup analyses. WIDER IMPLICATIONS OF THE FINDINGS Cost-effectiveness of a lifestyle intervention is more likely for longer follow-up times, and with live births conceived within 24 months as the effectiveness outcome. This effect was most profound in anovulatory women, in completers of the lifestyle intervention and in women ≥36 years old. This result indicates that the follow-up period of lifestyle interventions in obese infertile women is important. The scenario analyses performed in this study suggest that offering and reimbursing lifestyle intervention programmes in certain patient categories may be cost-effective and it provides directions for future research in this field. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The department of obstetrics and gynaecology of the UMCG received an unrestricted educational grant from Ferring pharmaceuticals BV, The Netherlands. B.W.J.M. is a consultant for ObsEva, Geneva. TRIAL REGISTRATION NUMBER The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1530.

KW - anovulation

KW - cost-effectiveness

KW - infertility

KW - lifestyle intervention

KW - obesity

KW - scenario analysis

UR - http://www.scopus.com/inward/record.url?scp=85021818524&partnerID=8YFLogxK

U2 - 10.1093/humrep/dex092

DO - 10.1093/humrep/dex092

M3 - Article

VL - 32

SP - 1418

EP - 1426

JO - Human Reproduction

T2 - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 7

ER -

Van Oers AM, Mutsaerts MAQ, Burggraaff JM, Kuchenbecker WKH, Perquin DAM, Koks CAM et al. Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Human Reproduction. 2017 Jul 1;32(7):1418-1426. https://doi.org/10.1093/humrep/dex092